Search Article Keyword:  

PubMed Submission Abstract PDF Feed Back Count: 5910 Download Count: 1465 

ISSN 1007-9327 CN 14-1219/R  World J Gastroenterol  2008 January 21; 14(3): 348-353
               TOPIC HIGHLIGHT
Epithelial restitution and wound healing in inflammatory bowel disease

Andreas Sturm, Axel U Dignass

Andreas Sturm, Department of Gastroenterology and Hepatology, Charité-Campus Virchow Clinic, Berlin, Germany

Axel U Dignass, Department of Gastroenterology, Hepatology, Oncology and Metabolic Diseases, Markus-Krankenhaus, Frankfurt/Main, Germany

Correspondence to: Axel U Dignass, MD, PhD, Medizinische Klinik I, Markus-Krankenhaus, Wilhelm-Epstein-Strasse 2, 60431 Frankfurt/Main, Germany.

Telephone: +49-69-95332201   Fax: +49-69-95332291

Received: May 16, 2007            Revised: July 4, 2007



Inflammatory bowel disease is characterized by a chronic inflammation of the intestinal mucosa. The mucosal epithelium of the alimentary tract constitutes a key element of the mucosal barrier to a broad spectrum of deleterious substances present within the intestinal lumen including bacterial microorganisms, various dietary factors, gastrointestinal secretory products and drugs. In addition, this mucosal barrier can be disturbed in the course of various intestinal disorders including inflammatory bowel diseases. Fortunately, the integrity of the gastrointestinal surface epithelium is rapidly reestablished even after extensive destruction. Rapid resealing of the epithelial barrier following injuries is accomplished by a process termed epithelial restitution, followed by more delayed mechanisms of epithelial wound healing including increased epithelial cell proliferation and epithelial cell differentiation. Restitution of the intestinal surface epithelium is modulated by a range of highly divergent factors among them a broad spectrum of structurally distinct regulatory peptides, variously described as growth factors or cytokines. Several regulatory peptide factors act from the basolateral site of the epithelial surface and enhance epithelial cell restitution through TGF-b-dependent pathways. In contrast, members of the trefoil factor family (TFF peptides) appear to stimulate epithelial restitution in conjunction with mucin glycoproteins through a TGF-b-independent mechanism from the apical site of the intestinal epithelium. In addition, a number of other peptide molecules like extracellular matrix factors and blood clotting factors and also non-peptide molecules including phospholipids, short-chain fatty acids (SCFA), adenine nucleotides, trace elements and pharmacological agents modulate intestinal epithelial repair mechanisms. Repeated damage and injury of the intestinal surface are key features of various intestinal disorders including inflammatory bowel diseases and require constant repair of the epithelium. Enhancement of intestinal repair mechanisms by regulatory peptides or other modulatory factors may provide future approaches for the treatment of diseases that are characterized by injuries of the epithelial surface.


© 2008 WJG. All rights reserved.


Key words: Intestines; Wound healing; Inflammation; Restitution


Peer reviewer: Peter L Lakatos, MD, PhD, Assistant Professor, 1st Department of Medicine, Semmelweis University, Koranyi S 2A, Budapest H1083, Hungary


Sturm A, Dignass AU. Epithelial restitution and wound healing in inflammatory bowel disease. World J Gastroenterol 2008; 14(3): 348-353  Available from: URL:  DOI:



The surface of the digestive tract is covered by epithelial cells that constitute an efficient physical barrier between the dietary and enteric flora pathogens found in the intestinal lumen and the individuum, but also allows an exchange between nutrients and the systemic circulation[1]. The epithelial defense mechanism can be categorized into three key components: pre-epithelial, epithelial and post-epithelial, the latter is represented by the lamina propria[2]. The pre-epithelial mucus barrier is composed of mucin associated with other proteins and lipids and forms a continuous gel into which a bicarbonate-rich fluid is secreted, maintaining a neutralizing pH at the epithelial surface. Phosphatidylcholine is the predominant surface bioactive phospholipid found within the gastrointestinal tract[3]. Intestinal epithelial cells secrete mucins and glycocalyx, which contain membrane-anchored negatively charged mucin-like glycoproteins and hydrophobic phospholipids[4]. The tight adherence of mucin to the apical surfaces of epithelia is owed to the existence of the specific complex between mucin oligosaccharides and the mucin binding protein of the apical mucosal membrane[5]. The hydrophobic lining of the luminal surface has an important functional role. It prevents microorganisms from getting into contact with and to adhering to the plasma membrane. It furthermore protects the mucosal epithelium against chemical and mechanical injuries[6]. Epithelial cells provide the second line of the mucosal defense system. Whereas in the upper digestive tract this layer consists of a stratified epithelium, the stomach, small, and large bowel are surfaced with a simple epithelial layer sealed by tight junctions[7]. When intact, the uptake of antigens, macro- and microorganism through this layer is restricted by luminal cell-surface structures. The mucosal surface epithelial cells are rapidly proliferating with a complete turnover every 24 to 96 h[8]. The proliferative compartment of epithelial cells is localized in the crypt region and is segregated from a gradient of increasingly differentiated epithelial cells present along the vertical axis of the functional villus compartment[9,10].



Damage and impairment of the intestinal surface barrier are observed in the course of various diseases and may result in an increased penetration and absorption of toxic and immunogenic factors into the body leading to inflammation, uncontrolled immune response, and disequilibrium of the homeostasis of the host. Thus, rapid resealing of the epithelial surface barrier following injuries or physiological damage is essential to preserve the normal homeostasis. Observations over the past several years have demonstrated the ability of the intestinal tract to rapidly reestablish the continuity of the surface epithelium after extensive destruction[11-14]. The continuity of the epithelial surface is reestablished by at least three distinct mechanisms. First, epithelial cells adjacent to the injured surface migrate into the wound to cover the denuded area. Those epithelial cells that migrate into the wound defect dedifferentiate, form pseudopodia-like structures, reorganize their cytoskeleton, and redifferentiate after closure of the wound defect. This process has been termed epithelial restitution and does not require cell proliferation[15]. Intestinal epithelial restitution occurs within minutes to hours both in vivo and in vitro. Secondly, epithelial cell proliferation is necessary to replenish the decreased cell pool. Third, maturation and differentiation of undifferentiated epithelial cells is needed to maintain the numerous functional activities of the mucosal epithelium. The separation of intestinal epithelial wound healing in three distinct processes is rather artificial and simplified. These three wound-healing processes overlap and distinct processes may not be observed in vivo where these processes overlap. The preservation of this barrier following injuries is regulated by a broad spectrum of structurally distinct regulatory factors, including cytokines, growth factors, adhesion molecules, neuropeptides and phospholipids[16-19]. However, this artificial and simplified model provides a tool to better understand the physiology and pathophysiology of intestinal epithelial wound healing. Moreover, deeper lesions or penetrating injuries will require additional repair mechanisms that involve inflammatory processes and non-epithelial cell populations. Inflammatory processes especially may interfere with epithelial cell migration and proliferation and thus modulate intestinal epithelial healing.



The epithelial cell populations of the intestinal mucosa are modulated by a number of factors that are present within the lumen, the epithelium itself or the underlying lamina propria (Table 1). Although the full variety of regulatory factors that play a role in the control of intestinal epithelial and non-epithelial cell populations has not been fully defined yet, there is increasing appreciation of the diversity of these factors in general and the importance of several specific peptide and non-peptide factors produced or released within the intestine. The identification and characterization of numerous regulatory peptide and non-peptide factors has led to the recognition of a network of interrelated factors within the intestine (Figure 1). The constituents of this network generally possess multiple functional properties and exhibit pleiotropism in their cellular sources and targets. As a result, this network is highly redundant in several dimensions[20]. Regulatory peptides especially seem to play a key role in intestinal epithelial wound repair, as they are abundantly detectable in the intestinal lumen, intestinal epithelium and the underlying lamina propria. Various members of several distinct regulatory peptide families have been recognized to modulate a broad spectrum of intestinal epithelial cell functions including cell migration, proliferation and/or differentiation (Figure 2). As outlined above the latter epithelial cell functions are highly relevant for the modulation of intestinal epithelial wound repair.



A broad spectrum of structurally distinct regulatory peptides is expressed from various cell populations within the mucosa of the intestinal tract. These regulatory peptides, conventionally designated as growth factors and cytokines play an essential role in regulating differential epithelial cell functions in order to preserve normal homeostasis and integrity of the intestinal mucosa[20-25]. The terminology of regulatory peptides is often confusing and arbitrary. The term cytokines is now increasingly used to describe a bunch of regulatory peptides that can be variously identified as regulatory peptides, peptide growth factors, interleukins, interferons and colony stimulating or hematopoetic stem cell factors. For the purpose of simplification, the term regulatory peptide or cytokine will be used in this paper to address all the different classes of regulatory peptide factors. Regulatory peptides can be reasonably classified on the basis of structural homologies and disparities into several discrete families. Peptide growth factor families and selected members with functional activities in the modulation of intestinal wound healing. In addition to growth factor families, a number of regulatory peptide factors, seemingly without structural similarities to other regulatory peptide family members like vascular endothelial cell growth factor (VEGF) and platelet-derived growth factor (PDGF) have been identified to be expressed within the intestinal tract and to modulate wound healing properties within the intestinal mucosa[25]. Furthermore, a countless number of classical cytokines like IL-1, IL-2, IL-15, IL-22 and IFN-g are expressed within the intestine and modulate numerous intestinal epithelial cell functions[26-30].

The various effects of a number of regulatory peptides on cell adhesion, migration, proliferation, differentiation, intestinal epithelial barrier function and angiogenesis suggest that these peptides are likely relevant factors for intestinal repair mechanisms. Both in-vitro and in-vivo studies have demonstrated that several growth factors and cytokines can enhance epithelial cell restitution[31,32]. A spectrum of growth factors and cytokines including EGF, VEGF, HGF, GLP-2, various FGF peptides, IL-1, IL-2 and IFN-g have been demonstrated to enhance epithelial cell restitution through a TGF-b-dependent pathway[33-36]. Interestingly, it appears that restitution-enhancing cytokines use different mechanisms to modulate TGF-b-peptide levels. While TGF-b, EGF, IL-1, IFN-g and HGF only increased the concentration of bioactive TGF-b, acidic and basic FGF and also IL-2 enhanced both the bioactivation of TGF-b and the expression of TGF-b mRNA and production of latent TGF-b peptide. This might reflect a different mechanism, by which acidic and basic FGF and also IL-2 modulate the synthesis and bioactivation of TGF-b. In contrast to the above mentioned growth factors and cytokines that are assumed to act from the basolateral site of the epithelial surface and that seem to stimulate intestinal epithelial restitution through a common TGF-b-dependent pathway, various members of the trefoil factor family (TFF Peptide family) appear to stimulate epithelial restitution in conjunction with mucin glycoproteins through a TGF-b-independent mechanism from the apical pole of the epithelium[35,37,38]. In this regard, our group recently also demonstrated that mesalamine promotes intestinal wound healing in vitro through a TGF-b-independent mechanism[39]. Recent studies suggest that modulation of repair mechanisms by trefoil peptides may be mediated by modulation of the E-cadherin/catenin complex[40,41]. However, a double-blind, randomized, placebo-controlled study treating 16 patients with mild-to-moderate left sided ulcerative colitis with enemas containing human recombinant trefoil factor family-3 did not reveal any additional benefit above that of adding 5-aminosalicylic acid alone[42].

It has been demonstrated, that keratinocyte growth factor (KGF) has an important function in wound re-epithelialization[43] and KGF expression is strikingly increased in surgical specimens from patients suffering from Crohn’s disease and ulcerative colitis[44]. Furthermore, in an experimental model of colitis, administration of KGF after but not before induction of colitis significantly ameliorated tissue damage demonstrating that exogenous KGF might promote IBD[45]. However, clinical studies treating patients with CD or UC with exogenous KGF have not been performed yet. In addition to their potent effects on epithelial restitution, a number of regulatory peptide factors act also as potent modulators of epithelial cell proliferation[17,18,32,46-49]. The most important modulators of intestinal epithelial cell proliferation include EGF and TGF-b which both act as potent stimulators of intestinal epithelial proliferation and TGF-b which inhibits intestinal epithelial cell proliferation and plays an important counterbalancing role in the regulation of intestinal epithelial cell proliferation. TGF-b is the most potent inhibitor of intestinal epithelial cell proliferation overriding the stimulatory effects of other stimulatory factors. The growth stimulating effect of IL-2, FGF peptides, IGF and HGF is rather moderate compared to the effects of EGF and TGF-b that stimulate epithelial cell proliferation five- to ten-fold in several intestinal epithelial cell lines in vitro[33,34,48,50]. Thus, it is not astonishing that in a randomized, double-blind clinical trial, after a 2-wk treatment period, patients receiving EGF enemas had a significant lower disease activity score than the control patients[51]. Concerning basic FGF, in a mouse DSS-model of experimental colitis, rectal administration of human recombinant basic FGF ameliorated the inflammation score and suppressed TNF-a gene expression in the colonic tissue[52,53]. Recently, the important role of Glucagon-like-peptide-2 (GLP-2), which is secreted from local neuroendocrine epithelial cells and promotes epithelial cell proliferation via stimulation of enteric neurons[54], has received more attention. GLP-2 demonstrating ability to ameliorate murine short bowel syndrome and experimental colitis[55,56] has consequently lead to clinical studies, evaluating the effect of GLP-2 in patients with short bowel syndrome.

However, it has also to be considered that cytokines have pleiotropic activities. For example, FGF also induces stricture formation in Crohn’s disease[57] and GLP-2 might have undesired effects in tumorogenesis[58], which might limit their therapeutic use. In addition, it has to be considered that these factors and also various non-peptide factors may act in an additive or even synergistic fashion which may potentiate their single effects. Notably, in addition to TGF-b the TGF-b family member Activin A has been identified to also inhibit epithelial cell proliferation, thus providing an additional mechanism to counterbalance the effects of proliferative factors present within the intestinal mucosa and to inhibit unrestrained cell growth[59,60].



In addition to the potent modulation of intestinal epithelial wound healing by regulatory peptides, it is increasingly appreciated that a broad spectrum of non-peptide factors exerts potent effects on intestinal epithelial cell populations and modulates those epithelial cell functions that are involved in the healing of intestinal injury (Table 2). These non-peptide factors encompass a broad spectrum of unrelated factors like phospholipids, nutrients (adenine) nucleotides, polyamines, short chain fatty acids (SCFA), products of the intestinal microflora, trace elements, pharmacological agents and other factors. Some of these factors are released by injured or dying mucosal cell populations (e.g. adenine nucleotides, phospholipids), other reach the intestinal mucosa via the intestinal lumen or the blood stream. These non peptide factors may exert growth factor like activities and exert potent effects on cell growth and differentiation in different cell populations including fibroblasts, vascular smooth muscle cells, endothelial cells and keratinocytes[20,35,61-63]. As some of these non-peptide factors are stable within the gastrointestinal tract despite high concentrations of acid, bile salts, proteases and microorganisms and as they exhibit only limited toxicity in vivo, they may serve as potential future targets to improve the armamentarium for the healing of mucosal epithelial injury.

Especially phospholipids and polyamines seem to be of special interest, as these non-peptide factors can be easily added to the regular diet and their overall content and biological activity can be modulated by various pharmacological agents[62,64-66]. Lysophosphatidic acid (LPA) is a key intermediate in the early steps of phospholipid biosynthesis and is rapidly produced and released from thrombin-activated platelets and growth factor stimulated fibroblasts to influence target cells by activating a specific 38-40 kDa G-protein coupled receptor that is expressed in many cells[67]. As a product of the blood-clotting process, LPA is a normal constituent of serum, where it is present in an albumin-bound form in physiologically relevant concentrations[64]. Major sources of LPA in the vicinity of injured epithelial cells are activated platelets, stimulated fibroblasts and presumably injured cells that release LPA due to non-specific phospholipase activation[67]. LPA promotes platelet aggregation and induces cellular tension and cell surface fibronectin assembly[68], which are also important events in wound repair suggesting an important role of LPA in inflammatory disorders. This was confirmed by our group when we demonstrated, that LPA not only promotes epithelial wound healing in vitro by a TGF-b-independent pathway, but also ameliorates experimental colitis in an experimental model of colitis in rats[61]. Interestingly, also lysophosphatidylethanolamine and lisofylline, which decreases lipid peroxidation, significantly reduced the degree of inflammation and necrosis in an experimental colitis model[69], demonstrating that the administration of anti-inflammatory lysophospholipids and suppression of pro-inflammatory lipid metabolites by lisofylline may provide new approaches to ameliorate intestinal inflammation. This beneficial effect could also be demonstrated in other diseases since lisofylline and its analogs reversed autoimmune diabetes in a non-obese diabetic (NOD) mouse model and thus might act as a potential treatment for Type 1 diabetes[70,71].

Many studies have reported that bone marrow cells may have the potential to contribute to the repair of many non-hematopoetic tissues, including the intestinal epithelial cells. Bone-marrow derived cells are capable of promoting regeneration of damaged intestinal epithelial cells[72]. However, the underlying effects are not fully understood[18]. Nevertheless, bone-marrow transplantation combined with immune-suppressive therapy improves epithelial wound healing[73] and recombinant granulocyte-macrophage colony-stimulating factor have a therapeutic effect in patients with active Crohn’s disease[74].



1         Madara JL, Nash S, Moore R, Atisook K. Structure and function of the intestinal epithelial barrier in health and    disease. Monogr Pathol 1990; 306-324   PubMed

2         Scheiman JM. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 1996; 25: 279-298


3         Schmitz MG, Renooij W. Phospholipids from rat, human, and canine gastric mucosa. Composition and metabolism of    molecular classes of phosphatidylcholine. Gastroenterology 1990; 99: 1292-1296   PubMed

4         Maury J, Nicoletti C, Guzzo-Chambraud L, Maroux S. The filamentous brush border glycocalyx, a mucin-like marker of    enterocyte hyper-polarization. Eur J Biochem 1995; 228: 323-331   PubMed

5         Slomiany A, Grabska M, Slomiany BL. Essential components of antimicrobial gastrointestinal epithelial barrier: specific    interaction of mucin with an integral apical membrane protein of gastric mucosa. Mol Med 2001; 7: 1-10   PubMed

6         Frey A, Giannasca KT, Weltzin R, Giannasca PJ, Reggio H, Lencer WI, Neutra MR. Role of the glycocalyx in regulating    access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment     and oral vaccine targeting. J Exp Med 1996; 184: 1045-1059   PubMed

7         Kraehenbuhl JP, Pringault E, Neutra MR. Review article: Intestinal epithelia and barrier functions. Aliment Pharmacol    Ther 1997; 11 Suppl 3: 3-8; discussion 8-9   PubMed

8         Potten CS, Kellett M, Rew DA, Roberts SA. Proliferation in human gastrointestinal epithelium using     bromodeoxyuridine in vivo: data for different sites, proximity to a tumour, and polyposis coli. Gut 1992; 33: 524-529


9         Cheng H, Leblond CP. Origin, differentiation and renewal of the four main epithelial cell types in the mouse small     intestine. III. Entero-endocrine cells. Am J Anat 1974; 141: 503-519   PubMed

10      Schmidt GH, Wilkinson MM, Ponder BA. Cell migration pathway in the intestinal epithelium: an in situ marker system    using mouse aggregation chimeras. Cell 1985; 40: 425-429   PubMed

11      McCormack SA, Viar MJ, Johnson LR. Migration of IEC-6 cells: a model for mucosal healing. Am J Physiol 1992; 263:    G426-G435   PubMed

12      Nusrat A, Delp C, Madara JL. Intestinal epithelial restitution. Characterization of a cell culture model and mapping of    cytoskeletal elements in migrating cells. J Clin Invest 1992; 89: 1501-1511   PubMed

13      Moore R, Carlson S, Madara JL. Rapid barrier restitution in an in vitro model of intestinal epithelial injury. Lab Invest    1989; 60: 237-244   PubMed

14      Feil W, Wenzl E, Vattay P, Starlinger M, Sogukoglu T, Schiessel R. Repair of rabbit duodenal mucosa after acid injury in    vivo and in vitro. Gastroenterology 1987; 92: 1973-1986   PubMed

15      Taupin D, Podolsky DK. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 2003; 4: 721-732   PubMed

16      Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205   PubMed

17      Dignass AU, Sturm A, Podolsky D. Epithelial injury and restitution. In: Domschke W, Stoll T, Brasitius TA, and Kagnoff    MF, editors. Intestinal Mucosa and its Diseases. Dordrecht-Boston-London: Kluwer Academic Publisher, 1999: 293-299

18      Okamoto R, Watanabe M. Cellular and molecular mechanisms of the epithelial repair in IBD. Dig Dis Sci 2005; 50    Suppl 1: S34-S38   PubMed

19      Okamoto R, Watanabe M. Molecular and clinical basis for the regeneration of human gastrointestinal epithelia. J    Gastroenterol 2004; 39: 1-6   PubMed

20      Dignass AU, Sturm A. Peptide growth factors in the intestine. Eur J Gastroenterol Hepatol 2001; 13: 763-770  PubMed

21      Wright NA. Aspects of the biology of regeneration and repair in the human gastrointestinal tract. Philos Trans R Soc    Lond B Biol Sci 1998; 353: 925-933   PubMed

22      Podolsky DK. Regulation of intestinal epithelial proliferation: a few answers, many questions. Am J Physiol 1993; 264:    G179-G186   PubMed

23      Fiocchi C. Cytokines and intestinal inflammation. Transplant Proc 1996; 28: 2442-2443   PubMed

24      Drucker DJ. Epithelial cell growth and differentiation. I. Intestinal growth factors. Am J Physiol 1997; 273: G3-G6      PubMed

25      Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 1999; 5: 44-60   PubMed

26      Reinecker HC, MacDermott RP, Mirau S, Dignass A, Podolsky DK. Intestinal epithelial cells both express and respond to    interleukin 15. Gastroenterology 1996; 111: 1706-1713   PubMed

27      Dignass AU, Podolsky DK. Interleukin 2 modulates intestinal epithelial cell function in vitro. Exp Cell Res 1996; 225:    422-429   PubMed

28      Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physiol 1997;    273: G769-G775   PubMed

29      MacDermott RP. Alterations of the mucosal immune system in inflammatory bowel disease. J Gastroenterol 1996;    31: 907-916   PubMed

30      Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diepolder H, Marquardt A, Jagla W, Popp A, Leclair S,    Herrmann K, Seiderer J, Ochsenkuhn T, Goke B, Auernhammer CJ, Dambacher J. IL-22 is increased in active Crohn's    disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol    Gastrointest Liver Physiol 2006; 290: G827-G838   PubMed

31      Holgate ST. Epithelial damage and response. Clin Exp Allergy 2000; 30 Suppl 1: 37-41   PubMed

32      Dignass AU. Mechanisms and modulation of intestinal epithelial repair. Inflamm Bowel Dis 2001; 7: 68-77   PubMed

33      Dignass AU, Tsunekawa S, Podolsky DK. Fibroblast growth factors modulate intestinal epithelial cell growth and    migration. Gastroenterology 1994; 106: 1254-1262   PubMed

34      Dignass AU, Lynch-Devaney K, Podolsky DK. Hepatocyte growth factor/scatter factor modulates intestinal epithelial cell    proliferation and migration. Biochem Biophys Res Commun 1994; 202: 701-709   PubMed

35      Wilson AJ, Gibson PR. Epithelial migration in the colon: filling in the gaps. Clin Sci 1997; 93: 97-108   PubMed

36      Bulut K, Pennartz C, Felderbauer P, Ansorge N, Banasch M, Schmitz F, Schmidt WE, Hoffmann P. Vascular endothelial    growth factor[VEGF164] ameliorates intestinal epithelial injury in vitro in IEC-18 and Caco-2 monolayers via induction of    TGF-beta release from epithelial cells. Scand J Gastroenterol 2006; 41: 687-692   PubMed

37      Dignass A, Lynch-Devaney K, Kindon H, Thim L, Podolsky DK. Trefoil peptides promote epithelial migration through a    transforming growth factor beta-independent pathway. J Clin Invest 1994; 94: 376-383   PubMed

38      Poulsom R, Begos DE, Modlin IM. Molecular aspects of restitution: functions of trefoil peptides. Yale J Biol Med 1996;    69: 137-146   PubMed

39      Baumgart DC, Vierziger K, Sturm A, Wiedenmann B, Dignass AU. Mesalamine promotes intestinal epithelial wound    healing in vitro through a TGF-beta-independent mechanism. Scand J Gastroenterol 2005; 40: 958-964   PubMed

40      Efstathiou JA, Noda M, Rowan A, Dixon C, Chinery R, Jawhari A, Hattori T, Wright NA, Bodmer WF, Pignatelli M.    Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin    complexes in human colon carcinoma cells. Proc Natl Acad Sci USA 1998; 95: 3122-3127   PubMed

41      Liu D, el-Hariry I, Karayiannakis AJ, Wilding J, Chinery R, Kmiot W, McCrea PD, Gullick WJ, Pignatelli M. Phosphorylation    of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest 1997; 77: 557-563     PubMed

42      Mahmood A, Melley L, Fitzgerald AJ, Ghosh S, Playford RJ. Trial of trefoil factor 3 enemas, in combination with oral 5-   aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2005;    21: 1357-1364   PubMed

43      Greenwood-Van Meerveld B, Venkova K, Connolly K. Efficacy of repifermin (keratinocyte growth factor-2) against    abnormalities in gastrointestinal mucosal transport in a murine model of colitis. J Pharm Pharmacol 2003; 55: 67-75      PubMed

44      Brauchle M, Madlener M, Wagner AD, Angermeyer K, Lauer U, Hofschneider PH, Gregor M, Werner S. Keratinocyte    growth factor is highly overexpressed in inflammatory bowel disease. Am J Pathol 1996; 149: 521-529   PubMed

45      Zeeh JM, Procaccino F, Hoffmann P, Aukerman SL, McRoberts JA, Soltani S, Pierce GF, Lakshmanan J, Lacey D,    Eysselein VE. Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats.    Gastroenterology 1996; 110: 1077-1083   PubMed

46      Alison MR, Sarraf CE. The role of growth factors in gastrointestinal cell proliferation. Cell Biol Int 1994; 18: 1-10     PubMed

47      Hu MC, Qiu WR, Wang YP, Hill D, Ring BD, Scully S, Bolon B, DeRose M, Luethy R, Simonet WS, Arakawa T, Danilenko    DM. FGF-18, a novel member of the fibroblast growth factor family, stimulates hepatic and intestinal proliferation. Mol    Cell Biol 1998; 18: 6063-6074   PubMed

48      Kurokowa M, Lynch K, Podolsky DK. Effects of growth factors on an intestinal epithelial cell line: transforming growth    factor beta inhibits proliferation and stimulates differentiation. Biochem Biophys Res Commun 1987; 142: 775-782     PubMed

49      Sonoyama K, Rutatip S, Kasai T. Gene expression of activin, activin receptors, and follistatin in intestinal epithelial    cells. Am J Physiol Gastrointest Liver Physiol 2000; 278: G89-G97   PubMed

50      Dignass AU, Stow JL, Babyatsky MW. Acute epithelial injury in the rat small intestine in vivo is associated with    expanded expression of transforming growth factor alpha and beta. Gut 1996; 38: 687-693   PubMed

51      Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral    mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003; 349: 350-357   PubMed

52      Matsuura M, Okazaki K, Nishio A, Nakase H, Tamaki H, Uchida K, Nishi T, Asada M, Kawasaki K, Fukui T, Yoshizawa H,    Ohashi S, Inoue S, Kawanami C, Hiai H, Tabata Y, Chiba T. Therapeutic effects of rectal administration of basic    fibroblast growth factor on experimental murine colitis. Gastroenterology 2005; 128: 975-986   PubMed

53      Dignass A, Sturm A, Podolsky DK. Epithelial injury and restitution. In: Domschke W, Stoll R, Brasitius TA, and Kagnoff    MF, editors. Intestinal Mucosa and its Diseases. Dordrecht: Kluwer Academic Publisher, 2002: 293-299

54      Bjerknes M, Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci    USA 2001; 98: 12497-12502   PubMed

55      Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002; 122:    531-544   PubMed

56      L'Heureux MC, Brubaker PL. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis.   J Pharmacol Exp Ther 2003; 306: 347-354   PubMed

57      Di Sabatino A, Ciccocioppo R, Armellini E, Morera R, Ricevuti L, Cazzola P, Fulle I, Corazza GR. Serum bFGF and VEGF   correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease. Inflamm Bowel Dis 2004;   10: 573-577   PubMed

58      Thulesen J, Hartmann B, Hare KJ, Kissow H, Orskov C, Holst JJ, Poulsen SS. Glucagon-like peptide 2 (GLP-2)    accelerates the growth of colonic neoplasms in mice. Gut 2004; 53: 1145-1150   PubMed

59      Dignass AU, Becker A, Spiegler S, Goebell H. Adenine nucleotides modulate epithelial wound healing in vitro. Eur J Clin    Invest 1998; 28: 554-561   PubMed

60      Dignass AU, Jung S, Harder-d'Heureuse J, Wiedenmann B. Functional relevance of activin A in the intestinal    epithelium. Scand J Gastroenterol 2002; 37: 936-943   PubMed

61      Sturm A, Cario E, Goebell H, Dignass AU. Lysophosphatidic acid enhances intestinal epithelial barrier function in vitro.   Gastroenterology 1999; 116: A934  

62      Sturm A, Schulte C, Schatton R, Becker A, Cario E, Goebell H, Dignass AU. Transforming growth factor-beta and    hepatocyte growth factor plasma levels in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;    12: 445-450   PubMed

63      Wilson AJ, Gibson PR. Short-chain fatty acids promote the migration of colonic epithelial cells in vitro. Gastroenterology   1997; 113: 487-496   PubMed

64      Jalink K, Hordijk PL, Moolenaar WH. Growth factor-like effects of lysophosphatidic acid, a novel lipid mediator. Biochim    Biophys Acta 1994; 1198: 185-196   PubMed

65      Moolenaar WH. LPA: a novel lipid mediator with diverse biological actions. Trends Cell Biol 1994; 4: 213-219     PubMed

66      Wang JY, McCormack SA, Viar MJ, Johnson LR. Stimulation of proximal small intestinal mucosal growth by luminal    polyamines. Am J Physiol 1991; 261: G504-G511   PubMed

67      Moolenaar WH. Lysophosphatidic acid signalling. Curr Opin Cell Biol 1995; 7: 203-210   PubMed

68      Olorundare OE, Peyruchaud O, Albrecht RM, Mosher DF. Assembly of a fibronectin matrix by adherent platelets    stimulated by lysophosphatidic acid and other agonists. Blood 2001; 98: 117-124   PubMed

69      Sturm A, Zeeh J, Sudermann T, Rath H, Gerken G, Dignass AU. Lisofylline and lysophospholipids ameliorate    experimental colitis in rats. Digestion 2002; 66: 23-29   PubMed

70      Cui P, Macdonald TL, Chen M, Nadler JL. Synthesis and biological evaluation of lisofylline (LSF) analogs as a potential    treatment for Type 1 diabetes. Bioorg Med Chem Lett 2006; 16: 3401-3405   PubMed

71      Yang Z, Chen M, Carter JD, Nunemaker CS, Garmey JC, Kimble SD, Nadler JL. Combined treatment with lisofylline and    exendin-4 reverses autoimmune diabetes. Biochem Biophys Res Commun 2006; 344: 1017-1022   PubMed

72      Okamoto R, Yajima T, Yamazaki M, Kanai T, Mukai M, Okamoto S, Ikeda Y, Hibi T, Inazawa J, Watanabe M. Damaged    epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat Med 2002; 8: 1011-1017


73      Okamoto R, Watanabe M. Prospects for regeneration of gastrointestinal epithelia using bone-marrow cells. Trends Mol    Med 2003; 9: 286-290   PubMed

74      Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage    colony-stimulating factor. Lancet 2002; 360: 1478-1480   PubMed

75      Wang JY, Johnson LR. Luminal polyamines stimulate repair of gastric mucosal stress ulcers. Am J Physiol 1990; 259:    G584-G592   PubMed

76      Makhoul IR, Kugelman A, Garg M, Berkeland JE, Lew CD, Bui KC. Intratracheal pulmonary ventilation versus    conventional mechanical ventilation in a rabbit model of surfactant deficiency. Pediatr Res 1995; 38: 878-885   PubMed

77      Dignass AU, Harder-d'Heureuse J, Jung S, Wiedenmann B. Glutamine enhances intestinal epithelial wound healing in    vitro. Clin Nutr 2000; 19 suppl 1: 24-28


S- Editor  Liu Y    L- Editor  Alpini GD    E- Editor  Li JL




Reviews Add

Related Articles:
Synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting
Non-invasive investigation of inflammatory bowel disease
Fertility and pregnancy in inflammatory bowel disease
Prevalence, predictors, and clinical consequences of medical adherence in IBD: How to improve it?
Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease